September 2, 2019
This feature highlights changes in clinical research organizations’ personnel.
Luis Vargas has been appointed medical director of medical affairs at Aerie Pharmaceuticals. Vargas previously was the vice president of medical affairs and the medical director at Revision Optics.
Amnicell appointed Helen Round as chief executive officer. Round most recently served as senior vice president of global marketing and business development for GN Hearing.
Bellus Health has appointed Catherine Bonucelli to chief medical officer. Bonucelli previously spent more than 20 years with AstraZeneca as global medicines clinical vice president for the inflammation, neuroscience and respiratory therapeutic area, and therapy area clinical vice president for respiratory and inflammation.
Albert Berger has been named chief executive officer and Nikhil Nayak to chief operating officer at Confirm Biosciences. Berger most recently served as vice president and general manager of Redwood Toxicology Laboratory. Nayak was the former chief marketing officer at Millennium Health.
Cyxone has named Malin Berthold project manager for the next step in the development of Cyxone’s clinical drug portfolio. Berthold previously was the senior scientific advisor for global evidence generation at Thermo Fisher Scientific in Stockholm, Sweden.
Eisai has announced the appointment of Priya Chaturvedi as vice president of global clinical quality assurance. Prior to joining Eisai, Chaturvedi was the executive director of clinical quality assurance and head of global good clinical practice for infectious disease and vaccines at Merck Research Labs.
Genetesis has appointed Peter Donato as chief business officer. Donato was previously the chief financial officer at Neuronetics.
Horizon Theraputics plc appointed Andy Pasternak vice president and chief business officer. Pasternak previously served as a management consultant with Bain & Company, leading Bain’s healthcare practices in America.
Octernal Theraputics has named Frank Hsu as chief medical officer and Rajesh Krishnan as senior vice president of chemistry manufacturing and controls and manufacturing. Hsu was previously vice president and head of oncology at immune design corporation prior to its acquisition by Merck. Krishnan was previously vice president of process development and manufacturing sciences at Dynavax Technologies Corporation.
Paradigm has appointed Kathy Galia as chief operating officer of its catastrophic care management division. Previously, Galia served as the associate vice president of medical solutions at The Hartford Fire Insurance Company.
PharmaCyte Biotech has named Manuel Hidalgo principal investigator for PharmaCyte’s clinical trial in locally advanced, inoperable Pancreatic Cancer at the Weill Cornell Medical Center. Hidalgo was recently appointed chief of the division of hematology and medical oncology at Weill Cornell Medical Center and New York-Presbyterian Weill Cornell Medical Center. Hidalgo was most recently a professor of medicine at Harvard Medical School and chief of the division of hematology and oncology as well as the director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center.
Ulrich Thienel has been named chief executive officer at ReAlta Lifesciences. Ulrich previously served as chief medical officer at Finch Therapeutics in Boston.
Reata Pharmaceuticals has appointed Manmeet Soni as chief financial officer and executive vice president and Jason Wilson as executive vice president of operations. Previously, Soni was the chief financial officer at Alnylam Pharmaceuticals. Wilson, who has been with Reata since 2006, was previously chief financial officer.
Edward Cox has been named vice president of regulatory affairs at Regeneron. Cox previously served as the director for the office of antimicrobial products at the center for drug evaluation and research at the FDA.
Sesen Bio has announced the appointment of Monica Forbes as chief financial officer. Previously Forbes was vice president of finance at Sesen Bio.
Michael Engsig has been named chief executive officer of Vaccibody. Engsig was most recently executive vice president of drug development counseling and business development at KLIFO.
Vaccitech has appointed Bill Enright as chief executive officer. Tom Evans, the former CEO will transition to the role of chief scientific officer. Previously, Enright spent more than a decade with Altimmune.